JP7088502B2 - 抗体医薬の効果増強用組成物 - Google Patents

抗体医薬の効果増強用組成物 Download PDF

Info

Publication number
JP7088502B2
JP7088502B2 JP2021545597A JP2021545597A JP7088502B2 JP 7088502 B2 JP7088502 B2 JP 7088502B2 JP 2021545597 A JP2021545597 A JP 2021545597A JP 2021545597 A JP2021545597 A JP 2021545597A JP 7088502 B2 JP7088502 B2 JP 7088502B2
Authority
JP
Japan
Prior art keywords
antibody
glucan
group
effect
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545597A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021049587A1 (https=
Inventor
康 梨井
真之 藤野
▲祐▼生子 守屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Center for Child Health and Development
Aureo Co Ltd
Original Assignee
National Center for Child Health and Development
Aureo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Center for Child Health and Development, Aureo Co Ltd filed Critical National Center for Child Health and Development
Publication of JPWO2021049587A1 publication Critical patent/JPWO2021049587A1/ja
Application granted granted Critical
Publication of JP7088502B2 publication Critical patent/JP7088502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2021545597A 2019-09-11 2020-09-10 抗体医薬の効果増強用組成物 Active JP7088502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019165722 2019-09-11
JP2019165722 2019-09-11
PCT/JP2020/034361 WO2021049587A1 (ja) 2019-09-11 2020-09-10 抗体医薬の効果増強用組成物

Publications (2)

Publication Number Publication Date
JPWO2021049587A1 JPWO2021049587A1 (https=) 2021-03-18
JP7088502B2 true JP7088502B2 (ja) 2022-06-21

Family

ID=74865712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545597A Active JP7088502B2 (ja) 2019-09-11 2020-09-10 抗体医薬の効果増強用組成物

Country Status (5)

Country Link
US (1) US12377116B2 (https=)
EP (1) EP4029509A4 (https=)
JP (1) JP7088502B2 (https=)
CN (2) CN114340669A (https=)
WO (1) WO2021049587A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240285672A1 (en) * 2021-06-22 2024-08-29 Gn Corporation Co Ltd Beta-glucan for preventing and/or treating fibrosis and related diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502167A (ja) 2002-09-04 2006-01-19 バイオポリマー エンジニアリング，インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
JP2017524737A (ja) 2014-07-10 2017-08-31 バイオセラ，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331482B2 (https=) 1974-05-18 1978-09-02
JPS5115632A (ja) 1974-06-22 1976-02-07 Kumiai Chemical Industry Co Satsuchusatsudanizai
JPS5480312A (en) 1977-12-08 1979-06-27 Asahi Glass Co Ltd Roll for use in production of float glass
JPS5937029B2 (ja) 1979-02-26 1984-09-07 三菱化学株式会社 陰極電着塗装法
JP2002204687A (ja) 2000-11-09 2002-07-23 Onaka Yasushi β−１．３−１．６グルカン（アウレオバシジウム培養液）の医療、保健、福祉、食品および各種産業分野での応用
JP4000078B2 (ja) 2003-03-07 2007-10-31 株式会社アウレオ 皮膚用保湿剤
JP4054697B2 (ja) 2003-03-07 2008-02-27 株式会社アウレオ 便秘改善剤
JP4369258B2 (ja) 2004-02-05 2009-11-18 株式会社アウレオ 免疫賦活剤
JP4268105B2 (ja) * 2004-09-09 2009-05-27 株式会社アウレオ β−グルカン含有組成物、その製造方法及び該組成物を含む飲食品若しくは皮膚用保湿剤
KR100709289B1 (ko) * 2005-09-23 2007-04-19 주식회사 글루칸 β-글루칸을 포함하는 항암 및 면역 기능 증강용 약학조성물
US20100068184A1 (en) 2006-11-02 2010-03-18 Aureo Co., Ltd. Living body healing accelerator
TWI496578B (zh) 2009-10-08 2015-08-21 Aureo Co Ltd 流感病毒感染症的治療劑
EP2508190B1 (en) 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
JP5242855B2 (ja) 2010-07-29 2013-07-24 国立大学法人北海道大学 免疫アジュバント
JP5554221B2 (ja) 2010-12-13 2014-07-23 株式会社アウレオ ウシの乳房炎の予防・治療用組成物及びウシの乳房炎の予防・治療方法
JP5937029B2 (ja) 2013-02-21 2016-06-22 国立大学法人北海道大学 Ｔｒａｉｌ発現亢進剤
JP6380968B2 (ja) 2013-10-22 2018-08-29 株式会社アウレオ 脂肪蓄積抑制剤
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EP3215163B1 (en) * 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
EP3400442A4 (en) * 2016-01-08 2019-06-26 Biothera, Inc. BETA-GLUCAN IMMUNOTHERAPIES WITH INFLUENCE OF THE MICRO ENVIRONMENT OF THE IMMUNE SYSTEM
JP6293187B2 (ja) 2016-03-22 2018-03-14 株式会社アウレオ 造血機能増進用の組成物、及び貧血の予防及び／又は改善用の組成物
JP2023531611A (ja) * 2020-06-16 2023-07-25 株式会社ソフィ 免疫増強および／または免疫均衡維持のためのならびにアジュバント使用のためのベータグルカン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502167A (ja) 2002-09-04 2006-01-19 バイオポリマー エンジニアリング，インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
JP2017524737A (ja) 2014-07-10 2017-08-31 バイオセラ，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLARK C. A. et al.，Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and Melanoma，Cancer Res.，2016年12月01日，76(23)，p. 6964-74
山崎 香織, 他6名，黒酵母の菌体外β-グルカンの経口投与による抗腫よう効果，日本農芸化学会大会講演要旨集，2004年03月05日，2004，p. 165, 3A07p24
木村 善行, 他5名，Colon 26移植マウスにおけるβ－グルカンの抗腫瘍および抗転移作用，日本癌学会総会記事，2004年，63，p. 456, P-1197

Also Published As

Publication number Publication date
CN120678911A (zh) 2025-09-23
CN114340669A (zh) 2022-04-12
WO2021049587A1 (ja) 2021-03-18
EP4029509A1 (en) 2022-07-20
US12377116B2 (en) 2025-08-05
US20220265698A1 (en) 2022-08-25
EP4029509A4 (en) 2023-10-18
JPWO2021049587A1 (https=) 2021-03-18

Similar Documents

Publication Publication Date Title
US6956120B2 (en) β-1.3-1.6 glucan (Aureobasidium medium)
CN100341521C (zh) 含β－葡聚糖的组合物
US20250114392A1 (en) Beta-glucan in combination with anti-cancer agents affecting the tumor micrenvironment
KR102476640B1 (ko) 종양세포 치사활성 및 항균성 조성물 및 방법
Devi et al. Immune augmentation and Dalton's Lymphoma tumor inhibition by glucans/glycans isolated from the mycelia and fruit body of Pleurotus ostreatus
JPH0454124A (ja) 抗ウィルス剤
US12156884B2 (en) Cancer treatment using β-(1-3)-(1-4)-glucan
JP4369258B2 (ja) 免疫賦活剤
US20050271613A1 (en) Beta-1, 3-1, 6-D-glucan and its use
JP7088502B2 (ja) 抗体医薬の効果増強用組成物
Sang et al. Glycyrrhetinic acid modified chlorambucil prodrug for hepatocellular carcinoma treatment based on DNA replication and tumor microenvironment
Jeong et al. Antitumor and immunomodulating activities of endo-biopolymers obtained from a submerged culture of Pleurotus eryngii
US6464981B2 (en) Therapeutic agent for a cancer and method of screening the same, and health-care auxiliary food
JP6842014B2 (ja) トロンボスポンジン１遺伝子発現亢進用組成物
JP2009143854A (ja) 創傷治癒促進剤
US20040001856A1 (en) Extract of lentinus lepideus and composition comprising the same having immune enhancing activity
JP4308350B2 (ja) シイタケ菌糸体抽出物を含有するｌａｋ活性スクリーニング物質およびそれを用いたｌａｋ活性スクリーニング法
JP2003155249A (ja) ＩｇＡ産生促進剤
KR100209180B1 (ko) 아세만난을 포함하는 약제학적 조성물
JP4165690B2 (ja) インターロイキン１２産生促進組成物の製造方法
Ahmed et al. Studies of ethanolic extract from Lentinus edodes on different cell lines and lymphocytes separated from cancer breast patients

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20210929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210929

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220531

R150 Certificate of patent or registration of utility model

Ref document number: 7088502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250